+61.9%
EBAY vs MRNA
-67.9%
+129.8%
-53.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.6% | +5.4% | -2.8% | +2.4% |
| 7D | +4.2% | -1.1% | +5.3% | +4.2% |
| 30D | +5.6% | +126.1% | -120.5% | -1.4% |
| 3M | -1.4% | +190.0% | -191.4% | -10.7% |
| 6M | +18.2% | +157.2% | -139.0% | +8.0% |
| YTD | +24.8% | +388.2% | -363.4% | +6.5% |
| 1Y | +18.0% | +467.0% | -449.0% | -1.6% |
| 3Y | +160.3% | +36.1% | +124.2% | +145.9% |
| All | +61.9% | -67.9% | +129.8% | +58.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling